BioCentury | Aug 2, 2019
Company News

Aug. 2 Company Quick Takes: Daiichi's cancer drug gets U.S. approval, plus BioMarin, Acorda, Stemline and more

...that missed analyst expectations, due in part to lower-than-expected sales of mucopolysaccharidosis drug Vimizim elosulfase alfa. Vimizim...
...1 receptor (C-FMS) Consensus estimates provided by FactSet. BioCentury Staff Elzonris (tagraxofusp-erzs, SL-401) Inbrija (CVT-301) pexidartinib (PLX3397) Vimizim, elosulfase alfa (BMN 110, bmn-110...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...chronic obstructive pulmonary disease BioMarin Inc. (NASDAQ:BMRN) China's National Medical Products Administration (NMPA) approved Vimizim elosulfase alfa...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

...BioMarin's Vimizim BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said China's National Medical Products Administration (NMPA) approved Vimizim elosulfase alfa...
...growth factor β 1 Jonathan Block, Associate Editor Emgality, galcanezumab-gnlm (LY2951742) Invossa, TissueGene-C (invossa-k inj., tg-c) Vimizim, elosulfase alfa (BMN 110, bmn-110...
BioCentury | Aug 9, 2018
Politics & Policy

China releases list of overseas drugs eligible for Priority Review

...Inc. (NASDAQ:AMGN); spinal muscular atrophy (SMA) therapy Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB); and Vimizim elosulfase alfa...
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

...figure out a way to translate that treatment to patients?” Emil Kakkis, Ultragenyx BioMarin’s Vimizim elosulfase alfa...
...during 1998-2009, he led development and commercialization of Aldurazyme and Naglazyme and started development of Vimizim...
BioCentury | May 4, 2017
Company News

BioMarin tops 1Q17 estimates

...expectations and a narrower-than-expected loss, driven by growth in sales of rare disease treatments Vimizim elosulfase alfa...
...revenue, up 28% from 1Q16 and beating a consensus estimate of $289 million. Sales of Vimizim...
...$0.51 loss in 1Q16 and beating a consensus estimate of a $0.29 loss. FDA approved Vimizim...
BioCentury | Apr 28, 2017
Clinical News

Brineura regulatory update

...received upon approval of Vimizim elosulfase alfa to Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) for $67.5 million. Vimizim...
BioCentury | Apr 27, 2017
Company News

FDA approves Brineura for Batten disease

...it. In 2014, BioMarin sold a Priority Review voucher it received upon approval of Vimizim elosulfase alfa...
BioCentury | Mar 15, 2017
Politics & Policy

NICE updates appraisal policies

...their high costs per QALY. They are Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Vimizim elosulfase alfa...
BioCentury | Jan 28, 2017
Regulation

Ultra-rare, ultra-slow

...The two most recent HST decisions from NICE found BioMarin Pharmaceutical Inc. ’s Vimizim elosulfase alfa...
Items per page:
1 - 10 of 121